June 4, 2020 / 2:15 AM / a month ago

BRIEF-Pharmaust Says Based On Preliminary Experiments Monepantel Treatment Reduces Sars-Cov-2 Cell-To-Cell Infectivity

June 4 (Reuters) - Pharmaust Ltd:

* BASED UPON PRELIMINARY EXPERIMENTS MONEPANTEL TREATMENT REDUCES SARS-COV-2 CELL-TO-CELL INFECTIVITY IN TISSUE CULTURE

* BASED UPON PRELIMINARY EXPERIMENTS MONEPANTEL TREATMENT REDUCES SARS-COV-2 VIRUS REPLICATION IN TISSUE CULTURE

* PLANS FURTHER VALIDATION OF PRELIMINARY RESULTS AS SOON AS POSSIBLE

* FILING PATENT APPLICATION SPECIFICALLY COVERING MONEPANTEL IN TREATMENT OF COVID-19 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below